ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

DOW JONES NEWSWIRES Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones. According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem. "We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million. A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful. Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months. Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283;

Stock News for Amgen Inc. (AMGN)
11/24/201508:38:03Healthcare's Greatest Dividend Stocks
11/24/201502:00:00European Commission Approves Amgen's BLINCYTO® (blinatumomab...
11/23/201508:50:00CVS Chooses New Cholesterol Drug for Caremark
11/23/201508:29:00CVS Chooses Repatha as New Cholesterol Drug for Caremark
11/23/201508:10:00Amgen Announces Repatha® Preferred Position On CVS Health Commercial...
11/21/201508:00:155 Things Amgen, Inc. Wants You to Know
11/20/201518:08:02The Best Healthcare ETF of the Week
11/20/201517:44:03Better Dividend Stock: Amgen or AstraZeneca PLC?
11/19/201516:00:00European Commission Approves Kyprolis® (carfilzomib) For Combination...
11/19/201510:03:08Amgen's Repatha Is Too Bloody Pricey for the U.K.
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/16/201516:00:00Amgen to Present IMLYGIC™ (Talimogene Laherparepvec) Data at t...
11/14/201507:21:02These 2 Companies Could Revolutionize Heart Disease Prevention
11/13/201512:02:03A Bounty of Data Pushes Amgen Higher by 14% in October
11/12/201516:46:32Statement of Changes in Beneficial Ownership (4)
11/12/201506:58:034 Observations You May Have Overlooked in Celgene's Q3 Earnings...
11/10/201514:58:26Why Aegerion Pharmaceuticals Is Crashing Today

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations